Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
NGL Fine Chem Ltd

| Q2 and H1 FY26 Earnings Conference Call

NEUTRAL SENTIMENT

Report Source

⬤18th Nov 25

Summary : NGL Fine-Chem reported strong Q2 and H1 FY26 growth driven by demand recovery, with new plant commissioning and U.S./EU market entry poised for future expansion, despite higher operating costs and competitive pressures.

Management Perspective positive : Management expressed optimism about sustained demand recovery and significant growth potential from capital investments. They highlighted strong Q2 and H1 FY26 financial performance and strategic progress in regulated markets.

Concall Report Analysis & Insights

Business Overview

  1. Q2 FY26 revenue increased 28.64% year-on-year to INR120.26 crores.
  2. EBITDA grew 48.43% to INR17.16 crores, with margins expanding to 14.27%.
  3. H1 FY26 revenue rose 21.82% to INR224.44 crores, and EBITDA increased 34.54%.
  4. The company experienced a steady, broad-based recovery in demand across its product portfolio.
  5. Outsourcing increased to 15-20% of production to meet strong demand.

Future Growth Prospects

  1. Capital expenditure programs are on track for completion by Q4 FY26, commissioning Q1 FY27.
  2. First API registration submitted to U.S. FDA in September 2025, with commercial production expected H2 FY27.
  3. New regulatory market capacity in the U.S. and EU is expected to significantly boost sales and profitability.
  4. Fluralaner, a star product, launched commercially in May 2025 and shows good growth.
  5. Targeting 15-18% EBITDA margins with increased scale of activities.

Management Insights

  1. Management is optimistic about sustained demand recovery and growth potential from capital investments.
  2. The company is focused on disciplined capital expenditure and timely project completion.
  3. Strategy includes leveraging a fully integrated supply chain for better margins.
  4. New plant capacity will primarily serve higher-margin U.S. and EU markets.
  5. Vigilance is maintained in navigating the competitive landscape.

Signs of Skepticism

  1. Management is 'cautiously optimistic' about sustained demand recovery after 10 quarters of flat movement.
  2. No specific guidance was provided for FY27 EBITDA margin range for the new plant.
  3. The exact quantum of new plant costs currently charged to P&L is not separately available.
  4. The company is unable to comment on future capacity creation by competitors.

Risk Factors

  1. Profit after tax for Q2 and H1 FY26 was marginally lower than the previous year.
  2. New plant operating expenses are expected to be INR1.2-1.5 crores per month from FY27.
  3. EBITDA breakeven for the new plant is not expected until FY28.
  4. U.S. FDA audit and approval process is lengthy, potentially delaying commercial sales.
  5. Competitive landscape has intensified with more players entering the market.

Good To Know

  1. The company has 3 CEPs and 5 ASMFs granted in Europe, with more in process.
  2. The first clean room under Phase 1 is already being used for manufacturing validation batches.
  3. The company is fully integrated for at least 60% of its products.
  4. Current working capital is INR45 crores, expected to grow to INR60 crores.
  5. U.S. and EU business is expected to yield gross margins of 55-60%.

Key Drivers

  1. U.S. FDA approval for API filings.
  2. New plant commissioning in Q1 FY27.
  3. Increased sales from regulated markets.
  4. Sustained demand recovery across products.

Key Analyst Discussions

Competitive Environment

  1. Analysts inquired about the competitive dynamics in India and from Chinese players.
  2. Questions were asked about the company's market share and overall market improvement.
  3. Queries focused on the company's competitive edge in terms of cost or integration.
  4. Discussions included whether any competitor capacity has exited the market.

Market Trends & Consumer Behavior

  1. Analysts sought clarification on the broad-based demand recovery and its sources.
  2. Questions were asked about the sustainability of demand growth and potential for price recoveries.
  3. Discussions included the reasons for prolonged pricing pressure in the API industry.
  4. Inquiries were made about the current growth trends observed in October and November.

Financial Highlights

  1. Analysts questioned the reasons for EBITDA margin decline over the last three years.
  2. Queries were raised about the incremental operating costs and depreciation from the new plant.
  3. Discussions included the peak debt required for capex and working capital.
  4. Questions arose regarding the impact of outsourcing on processing charges and future trends.
  5. Analysts asked about the expected gross margins from U.S. and European markets.

Product Composition

  1. Analysts asked for details on various CEPs and DMFs obtained for Europe.
  2. Questions were raised about the sales ramp-up from Europe in FY27.
  3. Discussions included the status and growth prospects of the fluralaner product.
  4. Queries focused on the specific products targeted for U.S. market filings.

Strategic Considerations

  1. Analysts questioned the strategy for growing in unregulated markets given current outsourcing levels.
  2. Inquiries were made about customer commitments for regulated market filings.
  3. Discussions included the ramp-up strategy for regulated market sales from the new plant.
  4. Questions were asked about the company's strategy to compete with established players in regulated markets.
  5. Analysts inquired about the capacity utilization of the new plant for different markets.